Efficacy and Safety of Early Initiation of Sodium-Glucose Cotransporter 2 Inhibitors in Acute Heart Failure: A Systematic Review and Meta-Analysis
Abstract
BACKGROUND AND OBJECTIVES
Acute heart failure (AHF) remains associated with high short-term mortality and rehospitalization despite advances in therapy. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) provide robust cardiovascular benefits in heart failure, but their efficacy and safety when initiated during AHF hospitalization are less established.
METHODS
Following a systematic search of 4 databases, a systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to evaluate the efficacy and safety of the initiation of dapagliflozin or empagliflozin during hospitalization for AHF, in addition to standard therapy. The primary outcome was all-cause mortality. Secondary outcomes included heart failure hospitalization (HFH), all-cause mortality at 1 month, cardiovascular death, serious adverse events leading to drug discontinuation, acute kidney injury (AKI), urinary tract infection (UTI), symptomatic hypotension, hypoglycemia, and diabetic ketoacidosis. Data were pooled using random-effects models, with sensitivity and meta-regression analyses.
RESULTS
Eight RCTs including 3,596 patients (1,817 SGLT2i; 1,779 control) were analyzed. SGLT2i initiation in AHF significantly reduced all-cause mortality (risk ratio [RR], 0.63; confidence interval [CI], 0.46-0.85; I²=0%) and all-cause mortality at 1 month (RR, 0.75; CI, 0.57-0.98; I²=0%). HFH and cardiovascular death did not differ significantly between groups. Pooled analyses showed no excess risk of…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 3,596 participants or records.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.